Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02080780 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects
A Phase 1 study of CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction], sponsored by Ventrus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02080780: Completed Phase 1 study of CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction], sponsored by Ventrus Biosciences.
NCT02080780 is a Phase 1 study of CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction] that has completed, run by Ventrus Biosciences. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02080780, a Phase 1 study of CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction], has completed, sponsored by Ventrus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the drug-drug interaction potential of clarithromycin XL on Diltiazem hydrochloride (DTZ) 2% cream.
Primary Outcome
To evaluate the drug-drug interaction potential of clarithromycin XL on Diltiazem hydrochloride (DTZ) 2% cream.
Conditions Studied
Interventions
- DRUG Clarithromycin XL
- DRUG 2% Diltiazem
Study Locations (1)
New Jersey
- TKL Research - Paramus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-09 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
What the finished NCT02080780 record still lists
NCT02080780 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction] appearing as the primary indexed condition, and to 2 interventions - of which Clarithromycin XL is the first listed.
NCT02080780 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT02080780 about?
NCT02080780 is a clinical study titled "Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects". The purpose of this study is to evaluate the drug-drug interaction potential of clarithromycin XL on Diltiazem hydrochloride (DTZ) 2% cream.
What is the current status of trial NCT02080780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-09. Estimated completion is 2013-10.
What conditions does trial NCT02080780 study?
This clinical trial studies the following conditions: CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction].
What interventions are being tested in trial NCT02080780?
The interventions under investigation include: Clarithromycin XL (DRUG), 2% Diltiazem (DRUG).
Who is sponsoring clinical trial NCT02080780?
This trial is sponsored by Ventrus Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02080780 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02080780's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia